HL
VRTX icon

HeadInvest LLC’s Vertex Pharmaceuticals VRTX Stock Holding History

HeadInvest LLC’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.16M Buy
2,332
+70
+3% +$31K 0.22% 95
2026
Q1 		$1.01M Sell
2,262
-45
-2% -$21K 0.21% 97
2025
Q4 		$1.05M Sell
2,307
-23
-1% -$9.91K 0.21% 94
2025
Q3 		$913K Sell
2,330
-200
-8% -$83.6K 0.19% 98
2025
Q2 		$1.13M Sell
2,530
-476
-16% -$219K 0.24% 79
2025
Q1 		$1.46M Buy
3,006
+311
+12% +$145K 0.28% 76
2024
Q4 		$1.09M Sell
2,695
-173
-6% -$80.2K 0.2% 86
2024
Q3 		$1.33M Buy
2,868
+410
+17% +$197K 0.25% 79
2024
Q2 		$1.15M Buy
2,458
+731
+42% +$317K 0.23% 84
2024
Q1 		$722K Buy
1,727
+679
+65% +$287K 0.14% 110
2023
Q4 		$426K Sell
1,048
-25
-2% -$9.23K 0.09% 156
2023
Q3 		$373K Hold
1,073
– – 0.08% 162
2023
Q2 		$375K Sell
1,073
-23
-2% -$7.75K 0.08% 164
2023
Q1 		$345K Sell
1,096
-50
-4% -$15K 0.08% 172
2022
Q4 		$331K Sell
1,146
-76
-6% -$23.2K 0.07% 171
2022
Q3 		$354K Buy
1,222
+10
+0.8% +$2.88K 0.08% 157
2022
Q2 		$342K Hold
1,212
– – 0.08% 163
2022
Q1 		$316K Sell
1,212
-17
-1% -$4.04K 0.06% 183
2021
Q4 		$270K Buy
1,229
+60
+5% +$11.7K 0.05% 206
2021
Q3 		$212K Sell
1,169
-27
-2% -$5.27K 0.04% 218
2021
Q2 		$241K Buy
1,196
+41
+4% +$8.58K 0.05% 204
2021
Q1 		$248K Buy
1,155
+122
+12% +$26.8K 0.05% 200
2020
Q4 		$244K Buy
+1,033
New +$237K 0.05% 189
2015
Q1 		– Sell
-3,000
Closed -$356K – 120
2014
Q4 		$356K Sell
3,000
-423
-12% -$47.6K 0.14% 84
2014
Q3 		$386K Hold
3,423
– – 0.15% 81
2014
Q2 		$324K Hold
3,423
– – 0.13% 89
2014
Q1 		$242K Hold
3,423
– – 0.1% 91
2013
Q4 		$254K Hold
3,423
– – 0.11% 90
2013
Q3 		$260K Hold
3,423
– – 0.11% 90
2013
Q2 		$274K Buy
+3,423
New +$252K 0.12% 92

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

HeadInvest LLC's VRTX Position: Q2 2026 in Review

HeadInvest LLC increased its Vertex Pharmaceuticals (VRTX) stake by 3.1% in Q2 2026, buying an estimated $31K and bringing the position to 2,332 shares worth $1.16M. The position accounts for 0.22% of the portfolio, ranked #95.

HeadInvest LLC first reported a position in VRTX in Q2 2013 and has held it in 30 quarters since. The position peaked at $1.46M in Q1 2025. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • HeadInvest LLC held 2,332 shares of Vertex Pharmaceuticals worth $1.16M as of Q2 2026.
  • HeadInvest LLC bought 70 Vertex Pharmaceuticals shares in Q2 2026, an estimated $31K.
  • Vertex Pharmaceuticals made up 0.22% of HeadInvest LLC's portfolio in Q2 2026, its #95 holding.
  • HeadInvest LLC first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 30 quarters since.
  • HeadInvest LLC's Vertex Pharmaceuticals position peaked at $1.46M in Q1 2025.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on HeadInvest LLC's 13F filing for Q2 2026, filed 14 Aug 2026.